【レポートの概要（一部）】
1. Report Overview
1.1 Global Translational Regenerative Medicine: Market Overview
1.2 Global Translational Regenerative Medicine Market Definition and Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction To Translational Regenerative Medicine
2.1 What Is Regenerative Medicine?
2.1.1 Translational Regenerative Medicine – From Bench to Bedside
2.2 Translational Regenerative Medicine – Market Breakdown
2.2.1 Stem Cell Therapy – Marketable Differentiation And Specialisation
2.2.1.1 How Embryonic Stem Cells (ESCs) Entered The Fray
2.2.1.2 Classifying Stem Cells by Potency
2.2.1.3 Stem Cells Categories: ESCs, SSCs, iPSCs
2.2.1.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
2.2.1.5 Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?
2.2.2 Tissue Engineering – In Vitro Manipulation for Therapeutic Purposes
2.2.3 Gene Therapies
2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy
2.3 Other Approaches to Regenerative Medicine
2.3.1 Small Molecules and Proteins – Scaffold-Based Delivery of Signalling Molecules
2.3.2 Cosmetic Applications of Regenerative Medicine
2.4 Regulation of Regenerative Medicine
2.4.1 Regulation of Regenerative Medicine Products in Europe
2.4.2 Regulation of Regenerative Medicine Products in the US
2.5 The Phases of Clinical Trials
2.6 Market Definition
2.6.1 Products Excluded from the Report
3. Translational Regenerative Medicine Market, 2016-2026
3.1 Global Translational Regenerative Medicine: Market Overview
3.1.1 Segments within the Global Translational Regenerative Medicine Market
3.2 The Global Translational Regenerative Medicine Market in 2014 and 2015
3.3 Global Translational Regenerative Medicine: Market Forecast 2016-2026
3.3.1 Market Sectors That Will Drive Translational Regenerative Medicine Growth
3.3.2 Global Translational Regenerative Medicine Market – Changing Market Shares By Sector 2016-2026
4. Stem Cell Therapies: Leading Applications, 2016-2026
4.1 The Global Market for Stem Cell Therapies, 2014 and 2015
4.1.1 Stem Cell Therapies: Currently Available Therapies
4.1.2 Haematopoietic Stem Cell Transplantation (HSCT)
4.1.2.1 HSCT for the Treatment of Multiple Sclerosis – A Possible Cure?
4.1.3 Stem Cell Orthobiologics
4.2 Stem Cell Therapies: Global Market Forecast 2016-2026
4.3 AlloStem (AlloSource)
4.4 Osteocel Plus (NuVasive)
4.4.1 Osteocel Plus: Sales Forecast 2016-2026
4.5 Trinity ELITE and Trinity Evolution (Orthofix)
4.5.1 Trinity ELITE and Trinity Evolution: Sales Forecast, 2016-2026
4.6 PureGen (AlphaTec Spine)
4.7 Other Approved Stem Cell Therapy Products, 2015
4.7.1 Cartistem (Medipost)
4.7.2 Cupistem (Anterogen)
4.7.3 Hearticellgram-AMI (Pharmicell)
4.7.4 TEMCELL/ Prochymal/ Remestemcel-L (Mesoblast)
4.7.4.1 TEMCELL/ Prochymal (Remestemcel-L): Sales Forecast 2016-2026
4.8 Development Pipeline for Stem Cell Therapies, 2016-2026
4.8.1 Late-Stage Pipeline for Stem Cell Therapies, 2015
4.8.1.1 StemEx and NiCord (Gamida Cell)
4.8.1.1.1 StemEx Shows Improved Survival at 100 Days – but FDA Wants Another Clinical Trial
4.8.1.2 Copper Chelator Based Technology
4.8.1.3 NiCord
4.8.1.3.1 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
4.8.1.3.2 NAM Technology Platform
4.8.1.4 Mesenchymal Precursor Cell Therapies (Mesoblast)
4.8.1.5 Adult Autologous CD34+ Cells (Baxter)
4.8.1.6 MyoCell (U.S. Stem Cell Inc.)
4.8.1.7 Cx601 (TiGenix)
4.8.1.8 Adipose-Derived Stem Cells (Cytori Therapeutics)
4.8.1.9 Stempeucel (Stempeutics Research)
4.8.1.10 C-Cure (Cardio3 BioSciences)
4.8.1.11 Other Late-Stage Stem Cell Therapies
4.8.2 Diabetes and Stem Cell Therapy
4.8.2.1 Mesenchymal Precursor Cells (Mesoblast)
4.8.2.2 VC-01 (ViaCyte Inc)
4.8.2.2.1 Clinical Development Efforts for VC-01 for the Treatment of Diabetes
4.8.3 Cardiovascular Disease and Stem Cell Therapy
4.8.3.1 Endometrial Regenerative Cells (MediStem, Intrexon)
4.8.3.2 AMR-001 (Caladrius Biosciences)
4.8.3.3 CAP-1002 (Capricor)
4.8.4 Stem Cell Therapy in Cancer
4.8.4.1 CLT-008 (Cellerant Therapeutics)
4.8.4.2 OncoCyte/BioTime – Targeting Cancer with Gene and Stem Cell Therapy
4.8.5 Stem Cell Therapy for Central Nervous System (CNS) Conditions
4.8.5.1 NurOwn (BrainStorm Cell Therapeutics)
4.8.5.1.1 Clinical Development Efforts for NurOwn, 2015
4.8.5.2 NSI-566 (Neuralstem)
4.8.5.3 NSI-189 (Neuralstem)
4.8.5.4 MultiStem (Athersys)
4.8.5.5 PDA-001 (Cenplacel-L, Celgene)
4.8.5.6 ALD-401 (Cytomedix)
4.8.5.7 ReN001 (ReNeuron)
4.8.6 Stem Cell Therapy for Eye Diseases
4.8.6.1 MA09-hRPE (Ocata Therapeutics)
4.8.6.2 HuCNS-SC (StemCells Inc.)
4.8.6.3 Collaboration And License Agreement Between Pfizer And The London Project to Cure Blindness
4.9 Stem Cells Therapy Market: Drivers and Restraints 2016-2026
5. Tissue Engineering Therapies: Leading Applications, 2016-2026
5.1 The Global Market for Tissue Engineered Therapies, 2014 and 2015
5.1.1 Tissue Engineering Therapies: Currently Available Therapies
5.2 Tissue Engineering Therapies: Global Market Forecast 2016-2026
5.3 Tissue Engineering in Wound Repair and Healing
5.3.1 Apligraf (Organogenesis)
5.3.1.1 Apligraf: Historical Sales Analysis
5.3.1.2 Apligraf: Sales Forecast 2016-2026
5.3.2 BioDfence and BioDfactor (BioD)
5.3.3 CureXcell (MacroCure)
5.3.4 Dermagraft (Organogenesis)
5.3.4.1 Dermagraft (Organogenesis): Sales Forecast 2016-2026
5.3.5 Epicel (Vericel)
5.3.6 Grafix (Osiris Therapeutics)
5.3.7 MySkin and CyroSkin (Regenerys)
5.3.8 ReCell (Avita Medical)
5.3.8.1 ReCell (Avita Medical): Sales Forecast 2016-2026
5.4 Tissue Engineering for Cartilage Repair
5.4.1 Autologous Chondrocyte Implantation (ACI)
5.4.2 Carticel (Vericel Corp.)
5.4.3 ChondroCelect (TiGenix, Sobi Partners)
5.4.4 DeNovo NT (Zimmer)
5.4.5 MACI (Vericel Corp.)
5.5 Other Available Tissue Engineering Therapies
5.5.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)
5.5.2 Gintuit (Organogenesis)
5.5.3 LAVIV (azficel-T), (Fibrocell Science)
5.5.4 Acellular Tissue Engineering Products
5.6 Tissue Engineering: Development Pipeline, 2016-2026
5.6.1 Pipeline Products for Autologous Chondrocyte Implantation
5.6.2 Tissue Engineering for Skin
5.6.3 Tissue Engineering for Liver Diseases
5.6.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)
5.6.4 Tissue Engineering for Cardiovascular Disease
5.6.5 Tissue Engineering for Eye Diseases
5.7 Future Prospects for Organ Transplantation and Tissue Engineering
5.8 Tissue Engineered Products Market: Drivers and Restraints 2016-2026
6. Gene Therapies: Leading Applications, 2016-2026
6.1 The Global Market for Gene Therapies, 2014 and 2015
6.2 Gene Therapies: Global Market Forecast 2016-2026
6.3 Currently Available Gene Therapy Products
6.3.1 Gendicine (Benda Pharmaceutical)
6.3.2 Oncorine (Shanghai Sunway Biotech)
6.3.3 Neovasculgen (Human Stem Cells Institute)
6.3.3.1 Neovasculgen (HSCI): Sales Forecast 2016-2026
6.3.4 Glybera (UniQure)
6.3.4.1 Glybera: Sales Forecast 2016-2026
6.4.1.4 IMLYGIC (talimogene laherparepvec) – (Amgen)
6.4.1.4.1 Clinical Trials and Development Efforts for IMLYGIC
6.4.1.4.2 Talimogene Laherparepvec (IMLYGIC) – Sales Forecast 2016-2026
6.4 Development Pipeline For Gene Therapies, 2016-2026
6.4.1 Late-Stage Pipeline Gene Therapies, 2015
6.4.1.1 Collategene (beperminogene perplasmid, AMG0001) – (AnGes MG/Vical)
6.4.1.2 ProstAtak (AdV-tk) – (Advantagene)
6.4.1.3 Trinam (taberminogene vadenovec) – (Ark Therapeutics)
6.4.1.4 AAV2-hRPE65v2 (Spark Therapeutics)
6.4.1.5 CG0070 (Cold Genesys)
6.4.2 Gene Therapy for Use in the Treatment of Diabetes
6.4.3 Gene Therapy Directed At Oncology Indications
6.4.4 Gene Therapy Directed at Neurological Diseases
6.4.5 Gene Therapy Directed at Tackling Haemophilia B
6.5 Gene Therapy Market: Drivers and Restraints 2016-2026
7. Leading National Markets for Translational Regenerative Medicine, 2016-2026
7.1 The Translational Regenerative Medicine Market by Region
7.1.1 The Global Distribution of Translational Regenerative Medicine in 2014 and 2015
7.2 Leading National Markets: Forecast 2016-2026
7.2.1 Changing Market Shares By Region, 2016-2026
7.3 Regional Translational Regenerative Medicine Markets: Analysis and Forecasts, 2016-2026
7.4 United States: The Largest Translational Regenerative Medicine Market
7.4.1 US Translational Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
7.4.2 US Translational Regenerative Medicine Market: Market Forecast 2016-2026
7.4.3 The Regulatory Framework for Regenerative Medicine in the US
7.4.4 The Impact of Ethical and Regulatory Reluctance to Embryonic Stem Cell Research and Its Impact on Funding
7.4.5 How Is the Ending of Patenting for Human Gene Products Affecting the Regenerative Medicine Market in the US?
7.5 Europe: A Fragmented Regenerative Medicine Market
7.5.1 European Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
7.5.2 European Regenerative Medicine Market: Market Forecast 2016-2026
7.5.3 Europe’s Unitary Patent System and Its Impact on the Future of Regenerative Medicine in the Region
7.5.4 Regulation of Regenerative Medicine in the European Union
7.5.5 UK: A Leading Research Centre for Regenerative Medicine in Europe
7.5.5.1 Regulation of Stem Cell Research in the UK
7.5.6 Russia: Rising Interest in Regenerative Medicine Research
7.6 Asia-Pacific: Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation
7.6.1 Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
7.6.2 Asia-Pacific Regenerative Medicine Market: Market Forecast 2016-2026
7.6.3 Australia: Encouraging Translational Regenerative Medicine
7.6.4 China: Encouraging Stem Cell R&D
7.6.4.1 Government Intervention into TRM Research in China
7.6.4.2 Regulation of Stem Cell Research in China
7.6.4.3 Commercialisation of Gene Therapy and Tissue Engineering Products in China
7.6.4.4 Medical Tourism Impacting Market Growth for Regenerative Medicine in China
7.6.5 Japan: Difficulty in Translating Research into Commercialisation
7.6.5.1 Research Funding: A Major Determinant of Growth in Japan’s Regenerative Medicine
7.6.5.2 Government Interventions in Promoting Stem Cell Research in Japan
7.6.5.3 Regulation of Regenerative Medicine in Japan
7.6.5.4 Accelerating Approvals of Regenerative Medicine Products in Japan
7.6.6 India: An Emerging Market for Regenerative Medicine
7.6.6.1 Efforts in Stem Cell Research in India
7.6.6.2 Unclear Guidelines Hindering Progression of Gene Therapy Research in India
7.6.7 South Korea: First to Approve Stem Cell Treatments
7.6.7.1 A Regeneration In South Korea’s Stem Cell Research Efforts
7.7 Rest of the World: Regenerative Medicine Conquering New Territories and Booming
7.7.1 Rest of the World Regenerative Medicine Market: Market Forecast 2016-2026
8. The Leading Companies in the the Translational Regenerative Medicine Market, 2016-2026
8.1 Translational Regenerative Medicine: A Hotbed for Innovation
8.2 Alphatec Spine
8.2.1 Alphatec Spine: Financial and Performance Analysis, 2009-2014
8.2.2 Alphatec Spine’s Shifting Focus from Regenerative Medicine to Medical Devices
8.3 Anterogen
8.3.1 Anterogen: Pipeline Analysis, 2015
8.4 Athersys
8.4.1 Athersys: Financial and Performance Analysis, 2010-2014
8.4.2 Athersys: Pipeline Analysis, 2015
8.4.2.1 MultiStem Technology – Potential Treatment for a Range of Diseases
8.5 Avita Medical
8.5.1 Avita Medical: Historical Financial and Performance Analysis, 2013-2015
8.5.2 Avita Medical: Regenerative Medicine Portfolio, 2015
8.5.3 Avita Medical: Pipeline Analysis, 2015
8.6 AxoGen
8.6.1 AxoGen: Historical Financial and Performance Analysis, 2010-2014
8.6.2 AxoGen: Regenerative Medicine Portfolio, 2015
8.6.3 AxoGen: Pipeline Analysis, 2015
8.8 Medipost
8.7.1 Medipost: Historical Financial and Performance Analysis, 2010-2014
8.7.2 Medipost: Regenerative Medicine Portfolio, 2015
8.7.3 Medipost: Pipeline Analysis, 2015
8.8 Mesoblast
8.8.1 Mesoblast Product Portfolio, 2015
8.8.2 Mesoblast: Historical Financial and Performance Analysis, 2010-2015
8.8.3 Mesoblast: Pipeline Analysis, 2015
8.8.3.1 NeoFuse
8.8.3.2 Chondrogen
8.8.3.3 Prochymal / TEMCELL
8.8.3.4 Other Recent Pipeline Acquisitions by Mesoblast
8.9 NuVasive
8.9.1 NuVasive Product Portfolio, 2015
8.9.2 NuVasive: Historical Financial and Performance Analysis, 2009-2013
8.9.3 NuVasive: Pipeline Analysis, 2015
8.10 Ocata Therapeutics
8.10.1 Ocata Therapeutics: Historical Financial and Performance Analysis, 2009-2014
8.10.2 Ocata Therapeutics: Pipeline Analysis, 2015
8.10.2.1 Retinal Pigment Epithelial Cell Therapy
8.10.3 Ocata’s Other Therapeutic Platforms
8.11 Organogenesis
8.11.1 Organogenesis RM Portfolio, 2015
8.11.2 Organogenesis: Pipeline Analysis, 2015
8.12 Osiris Therapeutics
8.12.1 Osiris Therapeutics: RM Portfolio, 2015
8.12.2 Osiris Therapeutics: Historical Financial and Performance Analysis, 2010-2014
8.12.3 Osiris Therapeutics: Pipeline Analysis, 2015
8.13 Pharmicell
8.13.1 Pharmicell: Historical Financial and Performance Analysis, 2010-2014
8.13.2 Pharmicell: Pipeline Analysis, 2015
8.14 Regenerys
8.14.1 Regenerys: RM Portfolio, 2015
8.14.2 Regenerys: Pipeline Analysis, 2015
8.15 TiGenix
8.15.1 TiGenix: Historical Financial and Performance Analysis, 2011-2014
8.15.2 TiGenix: Pipeline Analysis, 2015
8.16 UniQure
8.16.1 UniQure: Pipeline Analysis, 2015
8.17 Vericel Corporation (Formerly Aastrom Biosciences, Inc.)
9. Qualitative Analysis of the Translational Regenerative Medicine Market, 2015
9.1 Market Factors Influencing the Translational Regenerative Medicine Market
9.2 SWOT Analysis of the Translational Regenerative Medicine Market, 2016-2026
9.3 Strengths
9.3.1 Improvements in Regulatory Frameworks
9.3.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine
9.3.3 Strong Support from Governments in Multiple Regions
9.3.4 Increasing Ease of Product Commercialisation and Market Access
9.4 Weaknesses
9.4.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth
9.4.2 Lack of Funding from Venture Capital
9.4.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing
9.4.4 Successful Commercialisation of TRM Products Requires New Business Models
9.5 Opportunities
9.5.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
9.5.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth
9.5.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets
9.6 Threats
9.6.1 Ethical Concerns Limiting R&D in Regenerative Medicine
9.6.2 Difficulty Establishing an Evidence Base For Long-Term Efficacy Of TRM Therapies
9.6.3 Rate of Scientific Progress – A Major Determinant of TRM Market Growth
9.6.4 Restraints on Reimbursement May Slow Growth
9.7 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2016-2026
9.7.1 Threat of New Entrants
9.7.2 Threat of Substitutes
9.7.3 Power of Suppliers
9.7.4 Power of Buyers
9.6.5 Rivalry among Competitors
10. Research Interviews
10.1 Interview with Dr Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies
10.1.1 Naïve State Stem Cells Could Significantly Impact the Regenerative Medicine Market
10.1.2 On Relationships between Big Pharma and Smaller Biotech Companies in the Translational Regenerative Market
10.1.3 Growth of Minerva Biotechnologies
10.1.4 Possible New Commercial Applications for Regenerative Medicine
10.1.5 Translational Regenerative Medicine in Emerging Markets
10.1.6 iPS Cells – The Future of Stem Cell Therapies?
10.1.7 On Drivers and Restraints in the Translational Regenarative Medicine Market in 2016
10.2 Interview with Dr Yael Margolin, CEO of Gamida Cell Ltd.
10.2.1 Progress of NiCord in the Blood Cancer Indication
10.2.2 On Drivers and Restraints in the Blood Cancer Market in 2015
10.2.3 Growth of Gamida Cell Ltd.
11. Conclusion
11.1 Overview of Current Market Conditions and Market Forecast, 2014-2026
11.2 Leading Regenerative Medicine Segments in 2014 and 2015
11.3 Leading Regions in the Translational Regenerative Medicine Market in 2014 And 2015
11.4 Future Outlook for the Various Sectors within TRM, 2016-2026
11.5 R&D Pipeline Products Crucial to Future Market Growth
11.6 What Does the Future Hold for Regenerative Medicine?
12. Glossary
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
【レポート販売概要】
■ タイトル：展開再生医療の世界市場展望：幹細胞治療、組織工学、遺伝子治療■ 英文：Translational Regenerative Medicine: Market Prospects 2016-2026
■ 発行日：2016年1月
■ 調査会社：visiongain
■ 商品コード：VGAIN6022519
■ 調査対象地域：グローバル
- Tozadenant (パーキンソン病)：医薬品市場予測及び分析（～2022）Tozadenant (Parkinson’s Disease) - Forecast and Market Analysis to 2022 Summary Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly …
- 世界の乳酸及びポリ乳酸市場動向と予測（～2019）Lactic acid-based biodegradable polymers are projected to drive the demand for lactic acid across various industrial applications. The food & beverage segment is the second-largest application for lactic acid and will continue to drive the demand in this market. In this segment, lactic acid is mainly used as an acidulant, pH adjuster, and a preservative. The growth in this segment is projected to …
- 心臓カテーテル（医療機器）のグローバル新興国市場（2012-2018）BRICSS Cardiac Catheters market value is expected to reach US$1.7 billion by 2016, primarily supported by the product types - Electrophysiology (EP) Catheters, PTA Balloon Catheters, Guiding Catheters and ….etc. China accounts for nearly 27% of the market share and India claims more than 25%. In terms of CAGR, China is the fastest growing region while India and South Korea are just behind. Among t …
- 世界における歯科用生体材料の製品パイプライン動向2015Dental Biomaterials - Pipeline Review, 2015 Summary GlobalData's Medical Devices sector report, “Dental Biomaterials - Pipeline Review, 2015" provides an overview of Dental Biomaterials currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players invol …
- 股関節置換：グローバル市場分析と予測MediPoint: Total Hip Replacement - Global Analysis and Market Forecasts Summary Osteoarthritis has become a global public health concern with no cure. It is the most common form of arthritis that is primarily due to wear and tear of the joints. With the aging global population, this is an indication that is growing rapidly with the hip being one of the most common joints afflicted. While the prima …
- 水性エポキシ樹脂の世界市場：用途、需要先、地域別分析Waterborne epoxy resins exhibit high stability and excellent dilution efficiency. The waterborne epoxy resins offer different functionalities for a variety of applications such as automotive, construction, textiles, furniture and packaging. The aqueous epoxy resins include non-ionic epoxy-functional emulsifiers, which allow the emulsifier to become a part of the cured product with minimal impact o …
- ソーラーファーム自動化の世界市場2016-2020About Solar Farm Automation A solar tracker is a device used to orient a solar panel or align a solar reflector or lens toward the sun. It ensures that the solar modules remain in the best position to harness the maximum energy from the sun. A solar tracker is bound to the panel so that the position of the latter can be changed based on the sun's position throughout the year. Solar tracking is an …
- 世界の自動車センタースタック市場動向（2012-2016）TechNavio's analysts forecast the Global Automotive Center Stack market to grow at a CAGR of 3.57 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in automotive production and sales. The market has also been witnessing increasing demand for by-wire technologies. However, issues related to system integration could pose a challenge to the g …
- 販売実績管理（SPM）ソリューションの世界市場：インセンティブ/報酬管理、テリトリー管理、販売計画およびモニタリング、販売分析The increasing business progressions across organizations are significantly transforming the operational patterns for organizations worldwide. This has invariably led to the obligatory need to drive sales so as to derive more revenues for the company through enhanced customer engagement. With the definite realization that boosted sales force form the core valuable asset for organizations that defi …
- 家族/屋内エンターテイメントセンターの中東市場Family/indoor entertainment centers (FEC) are miniature indoor/outdoor amusement parks marketed toward families with small children to teenagers, and often are entirely indoors or associated with a larger operation such as a theme park. It offers a wide variety of entertainment activities for all age groups. FECs usually cater to sub-regional markets of larger metropolitan areas and are generally …
- 2014年戦略提言：世界のHIV/AIDS診断検査市場The report presents a detailed analysis of the AIDS diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the definition, epidemiology and etiology of AIDS and other retroviruses are reviewed. The report provides the 5-year test volume and sales forecasts by country for HIV-1/2, HIV Ag, HTLV-I/II, Western Blot and other confirmatory tests …
- 世界のセラミックス複合材料（CMC）市場About CMC Ceramic matrix composites (CMCs) are manufactured by strengthening a ceramic matrix with a refractory fiber. The ceramic matrix can be of various types including silicon carbide and alumina matrices, among others. The reinforcements can also be made in different forms, including continuous or short fibers and particles. Because of their superior material properties such as heat and wear …
- 透過型電子顕微鏡（TEM）の世界市場2015-2019About Transmission Electron Microscope The capacity of a microscope is limited by the wavelength of the light used. This limitation was particularly felt when the need to study the structure and arrangement of atoms and molecules arose. An electron microscope that uses a beam of accelerated electrons to view objects helps overcome this drawback. Electron microscopes can provide resolution up to 0. …
- 世界のグリッド最適化（電力網最適化）ソリューション市場（2014-2018）About Grid Optimization Grid optimization involves a wide array of prospective advances that gives utilities and grid operators digital control of the power delivery network. Although the concept of network optimization is simple, the practice is complex because it involves multiple variables and compensation. The factors that threaten the network instability include demands rise, the unpredictabl …
- 揚水発電（PHS）の世界市場2016-2026Visiongain has calculated that the global pumped hydro storage (PHS) market will see CAPEX of $3,853bn in 2016, including spending on new PHS installations and upgrades and expansions of existing projects. The report analyses the evolution of installed capacity and forecasts capital spending and capacity additions in 3 main technology submarkets (open-loop, closed-loop and innovative PHS), 14 nati …
